Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Cryoport, Inc. (NASDAQ:CYRX) President and CEO Jerrell Shelton sold 16,344 shares of common stock on June 24, 2025, at a weighted average price of $7.0586, for a total of $115,365. The transaction comes as the $365M market cap company’s stock shows significant momentum, gaining over 14% in the past week. According to InvestingPro data, the stock has demonstrated notable volatility with a beta of 1.84. The sales occurred in multiple transactions with prices ranging from $6.61 to $7.31.
On the same day, Shelton also exercised stock options to acquire 16,344 shares of Cryoport common stock at an exercise price of $5.00, for a total value of $206,720. These transactions occurred automatically pursuant to a trading plan adopted by the reporting person on June 3, 2025.
Additionally, on June 25, 2025, Shelton exercised options to acquire 25,000 shares at $5.00 per share.
Following these transactions, Shelton directly owns 937,419 shares of Cryoport, Inc.
In other recent news, Cryoport Inc . has completed the sale of its specialty courier business, CRYOPDP, to DHL Group for approximately $200 million in cash. This transaction is part of a strategic partnership with DHL, aimed at enhancing supply chain services for the global life sciences and healthcare sector. The deal provides Cryoport with additional capital to focus on its Life Science Services platform, particularly in the regenerative medicine market. Additionally, Cryoport reported its first-quarter 2025 earnings, revealing an earnings per share (EPS) of -$0.28, which exceeded the forecasted -$0.31. However, the company fell short of revenue expectations, generating $41 million against a forecast of $58.96 million. Despite this, the company saw a 10% year-over-year increase in revenue, driven by a 17% rise in life sciences services and a 33% growth in commercial cell and gene therapies. Cryoport has confirmed its full-year 2025 revenue guidance of $165-$172 million, anticipating continued growth in commercial cell and gene therapies. The company also highlighted its strategic focus on supply chain diversification and the potential impacts of tariffs on its operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.